Company news

Immutep Ltd news in 2019

Immutep Ltd's news releases, calls and decks from 2019, newest first.

View company

INSIGHT-004 clinical trial update

December 18, 2019

Immutep announces European patent grant for LAG525 antibody

November 13, 2019

Appendix 4C - quarterly

October 23, 2019

Immutep presents positive TACTI-mel melanoma trial data

October 14, 2019

Immutep receives A$2.5M R&D French Tax Incentive

October 9, 2019

Immutep expands Part A of TACTI-002 due to positive data

September 25, 2019

Immutep to receive GBP4M Milestone Payment from GSK

September 22, 2019

Japanese patent granted for LAG525 antibody

September 16, 2019

Immutep granted European patent for IMP321 in cancer

August 21, 2019

Appendix 4E & 2019 Full Year Statutory Accounts

August 20, 2019

Entitlement Offer Results & Shortfall Notification

August 1, 2019

Immutep Entitlement Offer Booklet

July 8, 2019

Immutep completes recruitment of AIPAC trial in MBC

June 24, 2019

Immutep granted Australian patent for eftilagimod alpha

June 20, 2019

Immutep completes recruitment of initial NSCLC cohort

June 13, 2019

First patient dosed in INSIGHT-004

June 5, 2019

Immutep granted European patent for eftilagimod alpha

May 22, 2019

More mature positive data for TACTI-mel trial presented

May 16, 2019

Immutep granted US patent for IMP321

March 21, 2019

IMP761 results presented at ECCO conference

March 7, 2019

Immutep doses First Patient in TACTI-002 Phase II Trial

March 6, 2019

TACTI-mel data presented at World Immunotherapy Congress

March 5, 2019

Half Year Accounts

February 27, 2019

Immutep enters into collaboration with CYTLIMIC

January 6, 2019

Decks in 2019